Car-T Treatment for Hematological Malignancies. (June 2020)

• Record Type: Journal Article
• Authors: Atrash, Shebli; Bano, Kulsum; Harrison, Bradley; Abdallah, Al-Ola
• Is Part Of: Journal of investigative medicine. Volume 68:Number 5(2020)
• Page Start: 956
• Page End: 964
• Publication Date: 2020-06
• Subjects: hematology; Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.1136/jim-2020-001290
• Languages: English
• ISSNs: 1081-5589

Abstract

Chimeric antigen receptor (CAR)-T-cell therapy has sparked a wave of optimism in hematological malignancies, reflected by the successful results of early clinical trials involving patients with pre-B-cell acute lymphoblastic leukemia, B-cell lymphomas and multiple myeloma. CAR-T-cell therapy is considered to be a novel immunotherapy treatment that has the potential for curing certain hematological cancers. However, as use of CAR-T-cell therapy has grown, new challenges have surfaced. These challenges include the process of manufacturing the CAR-T cells, the mechanisms of resistance that underlie disease relapse, adverse effects and cost. This review describes the published results of clinical trials and expected developments to overcome CAR-T resistance.